Should gene therapy be used for newborns with hemophilia?

Molecular Therapy

Volumn 7, Issue 1, 2003, Pages 7-8

  Parker Ponder, Katherine ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA GLUCURONIDASE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYTOKINE RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; VIRUS VECTOR;

ANTIBODY PRODUCTION; ARTHROPATHY; BLEEDING; CANCER RISK; COST OF ILLNESS; DEVICE INFECTION; DRUG EFFICACY; DRUG SAFETY; EXPRESSION VECTOR; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; NEWBORN DISEASE; NONHUMAN; NOTE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

VECTORS;

EID: 0037223470     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(02)00044-8     Document Type: Note

References (21)

1. Chuah, M. K., Collen, D., and VandenDriessche, T. (2001). Gene therapy for hemophilia. J. Gene Med. 3: 3-20.
2. Roth, D. A., Tawa, N. E. Jr., O'Brien, J. M., Treco, D. A., and Selden, R. F. (2001). Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia. A. N. Engl. J. Med. 344: 1735-1742.
3. Kay, M. A., et al. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24: 257-61.
4. Kelley, K., Verma, I., and Pierce, G. F. (2002). Gene therapy: reality or myth for the global bleeding disorders community? Haemophilia 8: 261-267.
5. Kashyap, R., and Choudhry, V. P. (2001). Management of hemophilia in developing countries. Indian J. Pediatr. 68: 151-157.
6. Berntorp, E. (2002). Progress in haemophilic care: ethical issues. Haemophilia 8: 435-438.
7. Isarangkura, P. (2002). Haemophilia care in the developing world: benchmarking for excellence. Haemophilia 8: 205-210.
8. WHF Global survey 2001, World Foundation of Hemophilia. http://www.wfh.org/.
9. Sarzotti, M. (1997). Immunologic tolerance. Curr. Opin. Hematol. 4: 48-52.
10. English, B. K., and Wilson, C. B. (2001). The neonatal immune system. In Clinical Immunology: Principles and Practice, (R. R. Rich, Ed.), 2nd edition, p. 779. Mosby, New York.
11. Fakharzadeh, S. S., and Kazazian, H. H. (2000). Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin. Thromb. Hemost. 26: 167-171.
12. Lusher, J. M. (2000). Inhibitor antibodies to factor VIII and factor IX: management. Semin. Thromb. Hemost. 26: 179-188.
13. Colowick, A. B., Bohn, R. L., Avorn, J., and Ewenstein, B. M. (2000). Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 96: 1698-1702.
14. Marshall, E. (2002). Clinical research. Gene therapy a suspect in leukemia-like disease. Science 298: 34-35.
15. Donsante, A., et al. (2001). Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 8: 1343-1346.
16. Waddington, S. N., et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood (in press), doi 10.1182/blood-2002-03-0779.
17. Nakai, H., et al. (1998). Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91: 4600-4607.
18. Walter, J., You, Q., Hagstrom, J. N., Sands, M., and High, K. A. (1996). Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc. Natl. Acad. Sci. USA 93: 3056-3061.
19. VandenDriessche, T., et al. (1999). Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc. Natl. Acad. Sci. USA 96: 10379-10384.
20. Xu, L., (2002). Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy, Mol. Ther. (in press).
21. Ponder, K. P., et al. (2002). Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc. Natl. Acad. Sci. USA 99: 13102-13107.